Disclaimer & Mission
Affiliation Disclaimer
This website is an independent educational resource. AshtonManual.org is not affiliated with, endorsed by, or connected to the late Professor C. Heather Ashton, DM, FRCP, her estate, or Newcastle University, where she conducted her pioneering clinical work.
The term “Ashton Manual” is used throughout this site solely as a reference to the widely recognized benzodiazepine tapering protocol that Professor Ashton developed and published. All content on this site is original, written and reviewed by the site’s publisher, Mark Leeds, D.O., and intended to inform patients and healthcare providers about benzodiazepine discontinuation.
Why This Site Exists
Professor C. Heather Ashton dedicated decades of clinical practice to helping patients safely withdraw from benzodiazepines. Her protocol, commonly known as the Ashton Manual, introduced a principle that remains, in our clinical experience, the most effective approach to benzodiazepine tapering: crossover to a long-acting agent (diazepam) before initiating a gradual taper.
This site exists because that principle is increasingly being set aside.
Current expert consensus, reflected in resources like the Maudsley Deprescribing Guidelines, favors tapering patients on whatever benzodiazepine they are already taking, often using liquid formulations or compounded dosage reductions (sometimes called “dry cuts”) to achieve smaller decrements. Prominent voices in the benzodiazepine deprescribing community have described the Ashton Manual as foundational but ultimately the older, original approach, now superseded by newer thinking.
We see it differently.
The Clinical Case for the Ashton Method
Our position, informed by years of direct clinical work with tapering patients, is that the Ashton crossover method is not merely historical. It is pharmacologically superior for many patients, and here is why.
Short-acting and intermediate-acting benzodiazepines like alprazolam, lorazepam, and clonazepam produce significant fluctuations in blood levels between doses. These fluctuations cause interdose withdrawal, a cycle of relief and emerging symptoms that keeps the nervous system in a state of repeated destabilization. Patients on these medications often experience anxiety, cognitive difficulty, and physical symptoms not because they are tapering too quickly, but because the drug itself is wearing off between doses.
Diazepam, the agent Professor Ashton recommended for crossover, has an elimination half-life of 20 to 100 hours, with active metabolites extending its effective duration even further. This creates a smooth, stable blood level that eliminates interdose withdrawal and allows the nervous system to gradually adapt as the dose is reduced.
Professor Ashton built her protocol on this reasoning decades ago, and it still rests on it.
Respecting the Conversation
We have deep respect for the clinicians, researchers, and advocates working in the benzodiazepine deprescribing space today. The organizations and individuals leading this work have raised awareness about benzodiazepine dependence and iatrogenic harm in ways that matter to patients.
We also recognize that there are legitimate clinical scenarios where tapering on the current benzodiazepine, using liquid titration or micro-tapering methods, is appropriate, particularly when a patient is stable, the current medication is long-acting, or crossover is contraindicated.
Our concern is that the field is moving away from the Ashton crossover method not because evidence has shown it to be inferior, but because it has been categorized as old. That characterization is a mistake. Patients deserve access to the clinical reasoning behind both approaches so they can make informed decisions with their providers.
That is what this site is for.
If you have questions about this site or its content, please contact us.